Cellectar Biosciences (CLRB) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
11 Nov, 2026Executive summary
Q3 progress centered on iopofosine I-131 for relapsed/refractory WM, with post-BTK inhibitor data supporting the planned accelerated-approval strategy.
Confirmatory Phase 3 preparation advanced, including site activation; a Phase 1b WM dosimetry study began, and CLR 125 development continued.
Financial highlights
Q3 2026 R&D expense was $5.44M vs. $2.5M in Q3 2025, reflecting Phase 3 preparation and increased CLR 125 trial activity.
Q3 2026 G&A expense was $2.67M vs. $2.3M in Q3 2025, primarily from higher professional fees and personnel costs.
Q3 operating expenses and operating loss were $8.10M vs. $4.85M; net loss was $7.97M vs. $4.44M, or $0.46 vs. $1.41/share.
9M 2026 operating expenses were $21.09M vs. $17.29M; net loss was $20.56M vs. $16.50M, or $1.81 vs. $7.82/share.
Outlook and guidance
First patient dosing in the randomized Phase 3 WM trial is targeted for Q1 2027; the trial plans ~100 patients per arm, with enrollment projected to take 18–24 months after first enrollment.
Accelerated NDA submission is targeted for H1 2027 and may occur at or after Phase 3 initiation; enrollment must be ongoing at the FDA decision. Full approval depends on superior PFS against a comparator.
Phase 1b WM dosimetry is expected to assess 20–30 newly diagnosed and relapsed patients; initial CLR 125 dosimetry and safety data were expected at a Q4 2026 medical meeting.
CLR 225 is Phase 1-ready, but trial initiation remains subject to corporate strategy.
Latest events from Cellectar Biosciences
- Iopofosine advances toward WM approval as the PDC pipeline expands into solid tumors.CLRB
Corporate presentation - Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials.CLRB
Corporate presentation - Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials.CLRB
Corporate presentation - Antigen-independent lipid raft targeting delivers diverse therapies with strong, durable efficacy.CLRB
Study update - Advanced clinical programs, strong efficacy, $34M cash, and 2027 NDA submission planned.CLRB
Q2 2026 - Lead radioconjugate shows robust efficacy in WM, with broad pipeline and strong financials.CLRB
Corporate presentation - Registering 51.9M shares for resale, company faces major regulatory and financial risks.CLRB
Registration filing - Shareholders will vote on governance, compensation, and capital-raising proposals, including major warrant exercises.CLRB
Proxy filing - Virtual Annual Meeting to vote on directors, stock plan, auditor, compensation, and warrants.CLRB
Proxy filing